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Abstract
Background: Irisin is a recently discovered myokine, involved in the browning of white adipose tissue. To date, its
function has been mainly associated with energy homeostasis and metabolism, and it has been proposed as a
promising therapeutic target for obesity and metabolic diseases. This is the first study investigating the role of irisin
in human breast cancer.
Methods: Participants included one hundred and one (101) female patients with invasive ductal breast cancer and
fifty one (51) healthy women. Serum levels of irisin, leptin, adiponectin and resistin were quantified in duplicates by
ELISA. Serum levels of CEA, CA 15–3 and Her-2/neu were measured on an immunology analyzer. The association
between irisin and breast cancer was examined by logistic regression analysis. The feasibility of serum irisin in
discriminating breast cancer patients was assessed by ROC curve analysis. Potential correlations with demographic,
anthropometric and clinical parameters, with markers of adiposity and with breast tumor characteristics were also
investigated.
Results: Serum levels of irisin were significantly lower in breast cancer patients compared to controls (2.47 ± 0.57 and
3.24 ± 0.66 μg/ml, respectively, p < 0.001). A significant independent association between irisin and breast cancer was
observed by univariate and multivariate analysis (p < 0.001). It was estimated that a 1 unit increase in irisin levels leads
to a reduction in the probability of breast cancer by almost 90 %. Irisin could effectively discriminate breast cancer
patients at a cut-off point of 3.21 μg/ml, with 62.7 % sensitivity and 91.1 % specificity. A positive association with tumor
stage and marginal associations with tumor size and lymph node metastasis were observed (p < 0.05, p < 0.01, p < 0.01,
respectively).
Conclusions: Our novel findings implicate irisin in breast cancer and suggest its potential application as a new
diagnostic indicator of the presence of disease.
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Background
Irisin is a newly discovered myokine, secreted from
muscle tissue as a cleavage product of fibronectin type
III domain containing 5 (FNDC5), after shedding of the
extracellular portion of the transmembrane protein into
extracellular space [1]. It has a molecular weight of
approximately 12 KDa and its amino acid sequence is
highly conserved among most mammalian species,
suggesting a highly conserved function [1]. Even though
the predominant source of irisin is skeletal muscle, it
was recently reported that adipose tissue also expresses
and secretes irisin, suggesting that it may function not
only as a myokine, but also as an adipokine [2]. Interest-
ingly, irisin has a different pattern of secretion depend-
ing on the anatomical location of adipose tissue, with
subcutaneous adipose tissue secreting more protein than
visceral adipose tissue [2]. A recent comprehensive im-
munohistochemical study of irisin expression in human
tissues indicated that the protein is locally produced in
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several central and peripheral tissues, potentially acting
as a gatekeeper of metabolic energy regulation [3].
Irisin appears to exert a variety of functions, which are
not yet fully elucidated. One of its main roles appears to
be associated with the browning of white adipose tissue
(beige cell formation), known to be involved in thermo-
genesis and energy expenditure [4, 5]. According to the
proposed mechanism, skeletal muscle releases several
myokines to the circulation during physical activity, in-
cluding peroxisome proliferator-activated receptor Y coac-
tivator 1α (PGC1α). The activation of PGC1α induces
FNDC5 secretion, which is proteolytically cleaved to irisin.
Irisin subsequently acts on both brown and white adipose
tissue (BAT and WAT, respectively) [6]. Its primary effect
on BAT is the activation of uncoupling protein 1 (UCP1)
in mitochondria, resulting in the dissipation of energy in
the form of heat also known as energy expenditure [7, 8].
The effect of irisin on WAT is the induction of BAT-
like phenotypic changes. More specifically, it increases
the expression of PGC1α and UCP1 as well as oxygen
consumption, while it downregulates genes that are
characteristic of WAT, process known as browning [1].
Altogether, these effects are associated with higher en-
ergy expenditure, which can further lead to the reduc-
tion of body weight and the improvement of metabolic
parameters. As a result, irisin was originally proposed
and investigated for its role as an exercise hormone and
as a potential new agent for the treatment of obesity
and metabolic diseases [9–18].
Obesity is a well-recognized risk factor for numerous
diseases including metabolic, cardiovascular, and malig-
nant diseases [19, 20]. Obese women are at an increased
risk of breast cancer and typically present more aggres-
sive disease, poorer outcomes and higher mortality rates
[21–25]. A number of mechanisms have been proposed
to mediate the link between obesity and breast cancer
development, including adipose tissue-induced increased
secretion of estrogens, insulin and insulin-like growth
factors and altered production of adipokines [26, 27].
Adipokines have been recognized to participate in breast
carcinogenesis providing a potential underlying molecu-
lar link between obesity and cancer development [28].
These factors can act on breast tissue in an endocrine,
paracrine and autocrine manner exerting direct and indir-
ect effects on breast cancer risk and progression [29–31].
Considering that alterations in adipokine secretion have
been closely associated with breast cancer, it would be
interesting to investigate the potential implication of irisin
in disease development through its function as an
adipokine.
The present study is the first attempt to explore the
role of irisin in human breast cancer, by quantitatively
determining serum levels of irisin in patients with inva-
sive ductal breast cancer and healthy individuals. We
aimed to examine the association between irisin and
breast cancer and to evaluate the ability of serum irisin
levels to discriminate between breast cancer patients and
controls. We analyzed potential associations between iri-
sin and various demographic, anthropometric and clin-
ical parameters, as well as with established markers of
obesity. Finally, potential correlations between irisin and
breast tumor characteristics were assessed.
Methods
Participants
One hundred one (101) female patients with primary
invasive ductal breast cancer were recruited from the
1st Department of Propaedeutic Surgery of Hippokratio
Hospital of Athens upon disease diagnosis. In addition,
fifty one (51) female healthy volunteers were recruited
during their annual breast cancer screening, after
exclusion of the presence of breast cancer or other sus-
picious breast lesions. Participants with other malig-
nancies, impaired liver function, severe psychiatric
conditions, cardiovascular diseases, metabolic diseases,
diabetes, chronic kidney disease, diseases of the central
nervous system, or under immunosuppressive agents
were excluded from the study. Similarly, subjects under
strenuous exercise within one month of the study were
also excluded. Clinicopathological characteristics of pa-
tients and controls are presented in Table 1. The study
protocol was approved by the Ethics Committee of the
Hippokratio Hospital of Athens, Greece. All partici-
pants gave their written informed consent prior to en-
tering the study.
Sample analysis
Peripheral venous blood samples were collected from all
patients preoperatively as well as from healthy controls.
Serum samples were prepared by centrifugation according
to standard protocols, aliquoted and stored at −80 °C until
assayed. Irisin levels were quantitatively determined in du-
plicates using commercial enzyme-linked immunosorbent
(ELISA) assays (AdipoGen International, Liestal, SW), ac-
cording to the manufacturer’s instructions. Serum levels
of leptin, adiponectin and resistin were also quantified by
corresponding ELISA assays (BioVendor, Brno, CZ).
Serum levels of cancer markers CEA, CA 15–3 and Her-
2/neu were measured on an Advia Centaur Immunology
Analyzer (Siemens, Tarrytown, US).
Statistical analysis
Normality of distribution was evaluated through the
Shapiro-Wilk test. Continuous variables are presented as
mean ± standard deviation (SD) when they are normally
distributed and as median (25th – 75th percentile) when
they are skewed. Categorical variables are summarized
as absolute (n) and relative frequencies (%).
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Associations between categorical variables were tested
by the use of contingency tables and the calculation of
chi-square tests without the correction of continuity or
Fisher’s exact test as appropriate. Associations between
continuous variables and categorical variables with two
categories were evaluated through Student’s t-test or
Mann–Whitney when continuous variables were nor-
mally distributed or skewed, respectively. Associations
between continuous variables and categorical variables
with three or more categories were evaluated through
one way ANOVA. However, due to multiple significance
comparisons, we used the Bonferroni correction in order
to account for the increase in Type I error.
Correlations between irisin levels and normally dis-
tributed continuous variables were evaluated by the
Pearson’s correlation coefficient, while Spearman cor-
relation coefficient was used to assess the correlation
between irisin levels and skewed continues variables.
Logistic regression analysis was performed in order
to determine whether the irisin levels are independ-
ently associated with the probability of women having
breast cancer. Patients’ characteristics found to be sig-
nificantly associated with the group were entered in
the model as potential confounders. The results are
presented as odds ratios (OR) and 95 % confidence
intervals (95 % CI).
Cut-off point analysis was used to identify the opti-
mal value of irisin levels that differentiates healthy
women from women with breast cancer. The thresh-
old was defined by the largest distance from the diag-
onal line of the receiver operating characteristic curve
(ROC) (sensitivity x (1-specificity)). Using the cut-off
points obtained from the analysis mentioned above,
the sensitivity and specificity of the index for the
aforementioned health outcomes were calculated. As
sensitivity was defined the probability of a Ca patient
having irisin level equal to or lower than a specific
value, and as specificity was defined the probability of
a healthy woman having irisin level higher than a
specific value. A probability value of 5 % was consid-
ered statistically significant. All statistical calculations
were performed on the SPSS version 21.0 software
(SPSS Inc, Chicago, II, USA).
Results
Demographic characteristics
Table 1 presents baseline demographic characteristics
of breast cancer patients and healthy controls. The two
groups had no significant differences regarding age,
gender and menopausal status. Significant differences
were observed in anthropometric characteristics, as
BMI was higher in cancer patients compared to con-
trols (p = 0.021). A significant difference was observed
regarding the presence of dyslipidemia, as a higher
percentage of controls was dyslipidemic (p < 0.001). As
far as cancer history is concerned, a significant differ-
ence was reported with a higher percentage of cancer
patients having a family history of breast and/or
gynecological cancer (p = 0.002), but not in personal
history of benign breast diseases or previous
neoplasms.
Comparison of irisin levels between patients and controls
Serum irisin levels were quantitatively determined in
breast cancer patients and healthy controls. Cancer pa-
tients exhibited significantly lower serum levels of irisin
compared to controls (2.47 ± 0.57 and 3.24 ± 0.66 μg/ml,
respectively, p < 0.001) (Fig. 1). According to simple logis-
tic regression analysis, there was a significant independent
association between irisin levels and the presence of breast
cancer (Table 2). It has been estimated that 1 unit increase
in irisin levels results to almost 87 % reduction in the
probability of women having breast cancer. The finding
remained significant after controlling for potential con-
founders, and more specifically for BMI, dyslipidemia and
family history of breast/gynecologic malignancy. After ad-
justment, it was estimated that 1 unit increase in irisin
levels leads to almost 90 % reduction in the probability of
women having breast cancer (Table 2).




Age (years) 55.7 ± 18.2 60.2 ± 13.7 0.131
Female gender 51 (100 %) 101 (100 %) -
Menopausal status 0.183
Pre-menopausal 17 (34.0 %) 24 (23.8 %)
Post-menopausal 33 (66.0 %) 77 (76.2 %)
Anthropometric characteristics
BMI (Kgr/m2) 25.7 ± 3.8 27.4 ± 5.1 0.021
BMI status 0.036
Normal weight 21 (42.0 %) 36 (36.4 %)
Overweight 24 (48.0 %) 35 (35.4 %)
Obese 5 (10.0 %) 28 (28.3 %)
Chronic Diseases




3 (6.0 %) 4 (4.0 %) 0.685
Personal history of
previous neoplasms
0 (0 %) 8 (7.9 %) 0.053
Family history of breast
and/or gynecological cancer
7 (14.0 %) 38 (38.0 %) 0.002
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Subsequently, ROC curve analysis was used to investi-
gate the potential application of irisin for the discrimin-
ation between patients with breast cancer and healthy
women. Our results indicate that irisin can effectively
discriminate between patients and healthy individuals at
an optimal value of 3.21 μg/ml. At this cut-off point, the
sensitivity and specificity of detection is 62.7 and 91.1 %,
respectively (Fig. 2).
Αssociations between irisin levels and tumor/patient
characteristics
Potential associations between serum irisin levels and
tumor characteristics were investigated within the breast
cancer group of patients (Table 3). Irisin levels were
positively associated with tumor stage (p = 0.039), in
particular stage I and stage III disease. Α marginal asso-
ciation with tumor size and lymph node metastasis was
observed (p = 0.084 and p = 0.098, respectively). There
was no significant association between irisin and tumor
grade or the presence of concurrent DCIS. Irisin levels
were not associated with ER, PR and c-erb-B2 status, or
with Ki67 and p53 expression. No associations with
serum levels of the established cancer markers CEA,
CA15-3 and Her2/neu were observed (Table 4).
In breast cancer patients, irisin levels were not
associated with BMI (p = 0.892). A positive association
with leptin was observed, but not with adiponectin or
resistin (Table 4). Finally, no associations between
irisin and age, dyslipidemia or family history of breast
and/or gynecological cancer were observed in the
patients’ group (p = 0.098, p = 0.712 and p = 0.236,
respectively).
Discussion
Irisin is a muscle-derived factor, discovered and charac-
terized three years ago [1]. Even though it is a relatively
new molecule, a significant number of reports has
already been published investigating its biology and
function in several healthy and disease states. Originally,
studies focused on the regulation of irisin by exercise
with variable observations [1, 9–15]. At the same time,
extensive research is being carried out on the role of iri-
sin in metabolic diseases, while new findings regarding
its implication in other chronic conditions gradually ac-
cumulate [32–42]. As far as the role of irisin in cancer is
concerned, current data are scarce and only include in
vitro reports [43, 44]. To our knowledge, the present
study is the first aiming to investigate the potential role
of the newly discovered irisin in human breast cancer.
Our results demonstrate that serum irisin levels are sig-
nificantly lower in breast cancer patients compared to
healthy controls. Logistic regression analysis indicated
that decreased irisin expression is closely associated with
the presence of breast cancer. Most importantly, multi-
variate analysis showed that serum irisin is an independ-
ent predictor of breast cancer. It was estimated that 1
unit increase in irisin levels leads to almost 90 % reduc-
tion in the probability of women having breast cancer.
According to ROC curve analysis, irisin can effectively
discriminate between patients and healthy individuals
with 62.7 % sensitivity and 91.1 % specificity at a cut-off
point of 3.21 μg/ml, suggesting its potential value in
breast cancer early detection.
Our observation of lower expression levels of irisin in
breast cancer is supported by the findings of Gannon et al.
evaluating the effect of various concentrations of irisin on
the behavior of malignant and non-malignant breast epi-
thelial cell lines [44]. The authors reported a significant
suppressive effect of irisin on cell number, migration and
Fig. 1 Scatter dot plots of serum irisin levels in patients with
invasive breast cancer and controls. Mean values ± standard
deviation are also denoted. Serum irisin levels were significantly
lower in breast cancer patients compared to controls (2.47 ± 0.57
and 3.24 ± 0.66 μg/ml, respectively, p < 0.001)
Table 2 Association of serum irisin levels with the probability of women having breast cancer (Logistic regression analysis)
Un-adjusted model Adjusted model
Patients’ characteristics OR (95 % CI) p-value OR (95 % CI) p-value
Irisin levels 0.131 (0.064–0.270) <0.001 0.107 (0.045–0.255) <0.001
BMI - - 1.117 (1.004–1.242) 0.041
Dyslipidemia - - 0.114 (0.039–0.330) <0.001
Family history of breast/gynecological neoplasms - - 3.774 (1.114–12.784) 0.033
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viability in breast cancer cells, the induction of apoptotic
cell death and the suppression of NFκB activity in malig-
nant cell lines. Based on these data, they hypothesized that
irisin may alter malignant characteristics similarly to other
myokines and affect the development and aggressiveness
of breast cancer [44]. It is thus reasonable to assume that
reduced levels of irisin would favor breast cancer initi-
ation, in agreement with our observations. The findings of
Gannon et al. oppose previous data that reported lack of
regulation of cell proliferation and malignant potential of
other obesity-related cancer cell lines, including endomet-
rial, colon, thyroid and esophageal, by irisin [43]. Never-
theless, these discrepancies have been attributed to
different experimental techniques [44]. Since these are the
only currently available data on the function of irisin in
cancer, further studies are warranted to elucidate its mo-
lecular effects during disease development and to identify
the implicated mechanisms.
Interestingly, a decreased expression of irisin has been
associated with other chronic conditions, known to be as-
sociated with altered energy expenditure and metabolism.
Most data arise from studies on patients with diabetes
mellitus type 2 (DMT2), indicating a close relationship be-
tween the presence of disease and decreased circulating
irisin levels [18, 32–34]. These observations are further
supported by reports of down-regulation of the FNDC5
gene in these patients [18, 45]. Similarly, circulating irisin
levels have been found significantly decreased in patients
with chronic kidney disease (CKD) [35–37]. Since the de-
velopment of DMT2 and CKD is often associated with
insulin resistance, it has been suggested that irisin may
play an important role in the pathology of insulin-
resistance related disorders while it may provide a novel
therapeutic target for the treatment of metabolic diseases
[18, 32, 35]. Two recent reports provide evidence for the
implication of irisin in the development of polycystic
ovary syndrome (PCOS) and also suggest that it may be a
marker of insulin resistance in these individuals [41, 42].
Adiponectin is another adipocyte-derived peptide
hormone, able to stimulate the sensitivity of peripheral
tissues to insulin, thus acting to enhance insulin sensi-
tivity and protect against conditions of insulin-
resistance [46]. Indeed, it has been documented that
decreased levels of adiponectin are associated with in-
creased insulin levels that accompany insulin resist-
ance [47]. Low circulating levels of adiponectin have
been observed in several diseases characterized by in-
sulin resistance and hyperinsulinemia, including obes-
ity, DMT2 and cancer [48–56]. Evidence from studies
on breast cancer cell lines and animal models indicate
that adiponectin can suppress cell proliferation, inhibit
tumor growth, increase apoptosis and inhibit angio-
genesis through multiple pathways [29–31]. Moreover,
epidemiological data support that it exerts a protective
role against breast cancer development, by displaying
anti-proliferating, pro-apoptotic, anti-estrogen and
anti-inflammatory properties [31]. More specifically,
several studies on breast cancer patients have observed
reduced adiponectin expression, particularly in post-
menopausal women, suggesting a close association
Fig. 2 ROC curve analysis assessing the feasibility of serum irisin as a diagnostic indicator of breast cancer. Serum irisin can discriminate between
breast cancer patients and healthy individuals at a cut-off point of 3.21 μg/ml, with 62.7 % sensitivity and 91.1 % specificity
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with breast cancer risk and providing a potential
mechanistic link between obesity and breast cancer
[53–55, 57–60]. Among the many mechanisms pro-
posed to mediate adiponectin function in breast can-
cer, the mitogenic effect of hyperinsulinemia appears
to be of particular importance [57]. According to our
results, serum levels of both irisin and adiponectin
were lower in breast cancer patients compared to con-
trols (data not presented) but there was no significant
association between them. Current knowledge on the
functions of irisin and the mechanisms involved in
exerting its actions is exceptionally limited and only al-
lows for hypotheses to be made. Nevertheless, the de-
creased expression levels of both molecules in our
cohort of patients support that irisin may play a role
similar to that of adiponectin. Moreover, irisin’s down-
regulation in conditions characterized by insulin resist-
ance suggest that this mechanism may be a major
determinant of its function. Whether the effect of iri-
sin on breast cancer can be attributed to obesity-
related hyperinsulinemia and insulin resistance extends
beyond the scope of this work, but is a particularly in-
teresting field of research that is worthy of thorough
investigation in future studies.
Interestingly, we found that irisin levels were higher in
stage III disease compared to stage I, resulting in a
positive association with tumor stage. Based on our ob-
servation of reduced levels of irisin in breast cancer
compared to controls, a further downregulation with the
extent or progression of the disease would possibly be
expected. This, however, may be a rather simplified hy-
pothesis. Cancer is an exceptionally complex disease,
accompanied by major dysregulation of a vast number of
interacting molecular mechanisms and signaling path-
ways. At present, it is still impossible to know how irisin
may behave and interact either in physiological condi-
tions or in disease states. One assumption for our obser-
vation would be that, after the establishment of breast
cancer, the secretion and metabolism of irisin may be
affected by other, yet unidentified, cancer-related path-
ways and factors, resulting in alterations in its expres-
sion levels. Otherwise, irisin might exert a different
function trying to counteract disease progression that is
reflected in its expression levels. Nevertheless, it should
be noted that even at stage III disease, irisin levels
remained significantly lower than in healthy controls.
Since this the first approach, our findings arise from a
Table 3 Association between irisin levels and breast tumor
characteristics
Characteristics N (%) Irisin levels (μg/ml) p-value
Tumor size (cm) 0.084
≤2.0 43 (48.3 %) 2.34 ± 0.52
2.1–5.0 31 (34.8 %) 2.58 ± 0.59
>5.0 15 (16.9 %) 2.65 ± 0.57
Grade 0.450
I 14 (14.3 %) 2.35 ± 0.59
II 29 (29.6 %) 2.42 ± 0.59
III 55 (56.1 %) 2.54 ± 0.56
Stage 0.039
I 21 (30.4 %) 2.31 ± 0.54
II 28 (40.6 %) 2.52 ± 0.58
III 20 (29.0 %) 2.75 ± 0.50a
Lymph nodes 0.098
Negative 40 (56.3 %) 2.44 ± 0.58
Positive 31 (43.7 %) 2.66 ± 0.53
Concurrent DCIS 0.161
No 34 (34.0 %) 2.37 ± 0.58
Yes 66 (66.0 %) 2.54 ± 0.56
ER status 0.966
Negative 24 (25.3 %) 2.46 ± 0.58
Positive 71 (74.7 %) 2.46 ± 0.56
PR status 0.904
Negative 30 (29.7 %) 2.47 ± 0.57
Positive 65 (68.4 %) 2.46 ± 0.57
c-erb-B2 status 0.226
Negative 64 (68.1 %) 2.41 ± 0.52
Positive 30 (31.9 %) 2.56 ± 0.66
Ki67 Value 0.243
<10 % 23 (24.5 %) 2.27 ± 0.54
10–15 % 16 (17.0 %) 2.53 ± 0.67
16–30 % 25 (26.6 %) 2.58 ± 0.54
>30 % 30 (31.9 %) 2.49 ± 0.53
P53 status 0.759
<10 % 52 (57.8 %) 2.45 ± 0.55
>10 % 38 (42.2 %) 2.49 ± 0.57
Data are presented as mean ± standard deviation
acompared to stage I after Bonferroni correction for multiple comparisons
Table 4 Associations between serum irisin levels, and serum




CEA (ng/ml) 1.36 (0.86–2.04) 0.082 0.455
CA 15–3 (U/ml) 15.90 (10.35–23.43) −0.067 0.539
HER2/neu (ng/ml) 11.80 (10.05–14.90) 0.147 0.274
Adiponectin (μg/ml)a 12.30 ± 4.46 0.174 0.201
Resistin (ng/ml) 5.06 (4.35–5.94) −0.203 0.134
Leptin (ng/ml) 18.99 (9.95–27.72) 0.399 0.003
aData are presented as mean ± standard deviation
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relatively restricted patient group and their verification
in larger cohorts of patients is mandatory.
According to our findings, irisin levels were not asso-
ciated with serum levels of the established cancer
markers CEA, CA15-3 and Her2/neu. Despite their
widespread use in routine clinical practice, it is well-
recognized that the traditional tumor markers are only
suitable for detection of recurrent or metastatic breast
cancer as well as for management and surveillance of
patients with advanced disease [61–63]. Their lack of
specificity and sensitivity for in situ and primary breast
cancer bears serious limitations and renders them rather
inappropriate biomarkers for screening and diagnosis of
low-volume disease [61, 63]. Thus, our observation of
no association between irisin and cancer markers is
rather expected and may further support the potential
diagnostic value of irisin.
Aiming to explore a potential link between irisin and
obesity in human breast malignancy, we investigated po-
tential correlations of irisin levels with body mass index
(BMI) and with levels of the adipokines leptin, adiponec-
tin and resistin in breast cancer patients. Our results
indicate that irisin was positively associated with leptin,
but not with adiponectin, resistin or BMI. Previously,
several studies have investigated irisin expression in rela-
tion to obesity. BMI is the most traditional and widely-
used measure of obesity. It has not yet been clarified if
irisin levels are associated with BMI, as some studies
have found positive correlations while others negative or
no correlation [9, 10, 16–18]. It was recently proposed
that irisin is positively correlated to BMI in healthy indi-
viduals but negatively correlated in subjects with meta-
bolic diseases, suggesting a different function according
to the metabolic state [64, 65].
Leptin is the most prominent and best studied adipo-
kine, and has been suggested to be implicated in the de-
velopment of hormone-dependent malignancies including
breast cancer [66]. Many studies have investigated leptin
as a risk factor for breast cancer mainly in postmeno-
pausal women, with conflicting and opposing findings
[67–73]. At the same time, few reports have explored the
role of leptin during disease progression and/or in relation
to its clinical behavior. Although data are diverse, studies
have provided evidence that increased expression of leptin
in patients with breast cancer is associated with large
tumor size, advanced tumor stage, high tumor grade and
lymph node metastasis [59, 60, 67, 74–76]. These observa-
tions have led to hypotheses that leptin is not only in-
volved in breast cancer initiation but also in disease
progression, and that it may be associated with more
aggressive phenotypes [59, 60, 67, 74, 75]. In addition, lep-
tin has been associated with distant metastasis and short
survival, suggesting that it may have a negative prognostic
value [76, 77]. Considering the potential relationship of
leptin expression with the characteristics and biological
behavior of breast tumors, we consider the association be-
tween irisin and leptin levels in our patients is a reflection
of the positive correlations of irisin with tumor stage and
marginally with tumor size and lymph node involvement.
The association of irisin levels with the presence of disease
and tumor characteristics but not with BMI suggests that
this factor is more likely to be related to systemic disease
and tumor extent rather than to adiposity, as previously
reported for leptin [76].
Altogether, our findings provide preliminary data for the
implication of irisin in breast cancer development and
suggest that it may serve as a potential novel biomarker of
the presence of disease. Cancer serum markers may have
a number of clinical applications including early diagnosis,
differential diagnosis, prognosis, prediction of response
and resistance to therapy, patient monitoring and surveil-
lance. In breast cancer, established tumor markers are
characterized by limited specificity and sensitivity preclud-
ing their use for screening and early diagnosis [60, 63].
Mammography, in combination with clinical examination
and breast self-examination, remains the primary modality
for breast cancer screening and early detection of the dis-
ease, and has significant contribution to the decrease in
mortality rates [78]. Nevertheless, mammography has im-
portant limitations particularly regarding the detection of
suspicious lesions in women with very dense breasts and
the early diagnosis of interval tumors [78]. As a result, im-
provements in the detection and early diagnosis of breast
cancer are required and are expected to have a major im-
pact on morbidity and mortality from the disease. In that
aspect, intensive research is being carried out to exploit
the use of novel serum biomarkers in screening, early
diagnosis and differential diagnosis of breast cancer [79].
The identification of irisin, as well as other novel proteins,
as candidate biomarkers that could assist in the early
detection of the disease is an exciting perspective, and re-
mains to be further investigated and verified by future
prospective studies.
Conclusions
Significant evidence implicating irisin in various diseases,
both metabolic and other chronic conditions, are grad-
ually accumulating. Nevertheless, there is still lack of
knowledge on its exact function and mode of action ei-
ther in healthy or in disease states. To our knowledge,
this is the first study attempting to investigate the role
and clinical relevance of irisin in human breast cancer.
Our findings provide significant preliminary evidence
that serum irisin may serve as a novel indicator for
breast cancer detection and early diagnosis. Forthcoming
studies aimed to clarify these aspects are awaited with
anticipation and are expected to add significant benefit
for these patients.
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